SUNRISE, Fla., Oct. 18, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) was among top scientists and physicians presenting cutting edge data at the Controversies and Advances in the Treatment of Cardiovascular Disease Conference in Los Angeles last week. A summary of data on the use of adult muscle stem cells (immature myoblasts) to treat advanced heart failure was presented by Howard Leonhardt, Bioheart’s co-founder and Chief Technology Officer. Bioheart is one of the only companies in phase II/III trials using stem cells. More than 400 patients have been treated with muscle stem cells and the following results have been published in peer reviewed journal articles:
